NCT07448805 Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit
| NCT ID | NCT07448805 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Centre Maribor |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-02-18 |
| Primary Completion | 2027-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-02-18 with a primary completion date of 2027-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Researchers at the Department of Intensive Internal Medicine and the Department of Endocrinology and Diabetology will conduct a study to verify the accuracy and safety of the new Syai Tag system for continuous glucose monitoring in patients in intensive internal care. Almost 150,000 people in Slovenia have diabetes, so keeping a close eye on blood sugar levels is key to preventing complications. The new sensors for continuous monitoring are available over the counter and certified as medical devices. The study will include at least 100 patients who will need blood sugar monitoring during their stay in the intensive care unit. Each patient will have two small sensors placed on each upper arm to continuously measure their blood sugar levels, but these values will not be visible to medical staff. At the same time, healthcare professionals will perform routine blood sugar measurements, and researchers will then compare the accuracy of both methods. The procedure is safe and painless, and patients will receive the same quality of care as usual.
Eligibility Criteria
Inclusion Criteria: * Admission to the intensive care unit * Expected ICU stay more than 24 hours * Presence of an arterial line Exclusion Criteria: * Age under 18 * Pregnancy * Skin changes that prevent sensor application
Contact & Investigator
Nika Kravos Tramšek, MD PhD
PRINCIPAL INVESTIGATOR
UMC Maribor
Frequently Asked Questions
Who can join the NCT07448805 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07448805 currently recruiting?
Yes, NCT07448805 is actively recruiting participants. Contact the research team at nikakravos@gmail.com for enrollment information.
Where is the NCT07448805 trial being conducted?
This trial is being conducted at Maribor, Slovenia.
Who is sponsoring the NCT07448805 clinical trial?
NCT07448805 is sponsored by University Medical Centre Maribor. The principal investigator is Nika Kravos Tramšek, MD PhD at UMC Maribor. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.